Madrigal Pharmaceuticals, Inc. (MDGL)

In the six months leading up to February 2026, Madrigal Pharmaceuticals' stock gained 7.3%. However, the stock price declined following the report of Q4 and full-year 2025 financial results, which included an EPS miss despite revenue exceeding expectations. The Q4 2025 EPS came in at -$2.57, missing the consensus estimate of $0.04. Despite the earnings miss, Madrigal reported strong Rezdiffra net sales of $321.1 million for Q4 2025 and $958.4 million for the full year 2025, with over 36,250 patients on the therapy by year-end 2025. There was also notable insider selling activity exceeding $5 million. Analyst sentiment remains generally positive, with a consensus "Moderate Buy" rating and an average 1-year price objective of approximately $685.31 as of April 2026.

There is no explicit information indicating significant demand seasonality for Madrigal Pharmaceuticals' primary product, Rezdiffra. The company emphasizes strong underlying patient demand and consistent quarter-over-quarter growth since its launch. While there might be "first-quarter dynamics and increased gross-to-net pressures due to revised contracting terms" that could affect revenue recognition in specific quarters, these appear to be related to financial and contractual aspects rather than inherent seasonal fluctuations in patient demand for the medication.

Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics for MASH. Their flagship product is Rezdiffra, a liver-directed thyroid hormone receptor-β agonist, which has received accelerated approval from the FDA and conditional approval from the European Commission for treating adults with noncirrhotic MASH with moderate to advanced liver fibrosis. Madrigal is also studying Rezdiffra for MASH with compensated cirrhosis and expanding its pipeline with additional programs, including licensing agreements for an oral GLP-1 receptor agonist and a Phase 2 DGAT-2 inhibitor.

Madrigal Pharmaceuticals is headquartered in West Conshohocken, Pennsylvania, United States, with operations in the United States and Europe. Its international headquarters is located in Zug, Switzerland. Following European Commission approval, Madrigal launched Rezdiffra in Germany in September 2025.

Madrigal Pharmaceuticals' brand reputation has been positively influenced by the FDA approval and launch of Rezdiffra, establishing the company as a leader in MASH treatment. The company's CEO highlighted that 2025 was a "defining year" for Madrigal, solidifying its position as the "undisputed leader in MASH" with nearly $1 billion in Rezdiffra sales in its first full year. However, the Q4 2025 earnings miss and concerns over competition from GLP-1 agonists could be perceived as minor setbacks. The company's efforts to expand its pipeline and secure patent protection reinforce its commitment to long-term leadership in the MASH space.

Madrigal Pharmaceuticals, Inc. is primarily owned by institutional shareholders, who hold 102.74% of the stock, and insiders, who hold 290.17%. Retail investors hold a negligible percentage. As of April 10, 2026, the company has 398 institutional owners and shareholders holding a total of 23,596,993 shares. Major institutional owners include Baker Bros. Advisors Lp, RTW Investments, Lp, Vanguard Group Inc, Avoro Capital Advisors LLC, Paulson & Co. Inc., BlackRock, Inc., Janus Henderson Group Plc, State Street Corp, Wellington Management Group Llp, and Geode Capital Management, Llc. The largest individual shareholder is Bruce Kovner, owning 22.94 million shares, representing 99.99% of the company.